Clearmind Medicine (NASDAQ:CMND) Major Shareholder Sells $27,022.92 in Stock

by · The Markets Daily

Clearmind Medicine Inc. (NASDAQ:CMND – Get Free Report) major shareholder Financial Lp Hrt sold 225,191 shares of Clearmind Medicine stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $0.12, for a total value of $27,022.92. Following the completion of the transaction, the insider owned 1,838,075 shares in the company, valued at approximately $220,569. This represents a 10.91% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Financial Lp Hrt also recently made the following trade(s):

  • On Wednesday, June 10th, Financial Lp Hrt purchased 2,159,052 shares of Clearmind Medicine stock. The shares were purchased at an average cost of $0.15 per share, for a total transaction of $323,857.80.

Clearmind Medicine Stock Performance

Shares of CMND stock remained flat at $3.34 during mid-day trading on Friday. The stock had a trading volume of 160,621 shares, compared to its average volume of 1,154,189. The business has a fifty day moving average price of $6.37 and a two-hundred day moving average price of $17.01. The stock has a market capitalization of $3.40 million, a P/E ratio of -0.02 and a beta of 0.64. Clearmind Medicine Inc. has a 12-month low of $2.10 and a 12-month high of $524.00.

Clearmind Medicine (NASDAQ:CMND – Get Free Report) last issued its quarterly earnings results on Thursday, March 12th. The company reported ($33.20) earnings per share (EPS) for the quarter.

Analysts Set New Price Targets

Separately, Wall Street Zen raised Clearmind Medicine to a “sell” rating in a report on Saturday, May 23rd.

Check Out Our Latest Report on Clearmind Medicine

Clearmind Medicine Company Profile

(Get Free Report)

Clearmind Medicine, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel psychoplastogen-based therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages a proprietary chemistry platform to design small-molecule compounds that promote rapid and sustained neural plasticity without the hallucinogenic effects typically associated with psychedelic agents. By targeting fundamental mechanisms of synaptic growth and repair, Clearmind aims to address conditions ranging from mood and anxiety disorders to cognitive impairment in dementia.

Clearmind’s pipeline includes multiple preclinical and early clinical candidates.

Further Reading